SNY Sanofi-Aventis
5,130
$49.03
$0.02
(0.04%)
| Watchers | 5,130 |
| 52-Wk Low | $42.63 |
| 52-Wk High | $55.72 |
| Market Cap | $122.8B |
| Volume | 210,381.00 |
| 52-Wk High | $55.72 |
| 52-Wk Low | $42.63 |
Excess Deaths In Japan Hit 115,000 Following 3rd COVID Shot; New Study Explains WhyZero Hedge • 11 days ago
Excess Deaths In Japan Hit 115,000 Following 3rd COVID Shot; New Study Explains Why
Authored by Joe Wang via The Epoch Times (emphasis ours),
A new study on harms resulting from the...
Share to Feed
AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.
read more...
read more...
Sanofi reports Q1 operating income at 2.8 billion euros, down 14.7%. Beat consensus EPS at $0.97. Sales reach $11.36 billion, led by Dupixent's 24.9% surge. Vaccine sales up 5.6%. Expecting Dupixent...
Sanofi CEO Paul Hudson on Q1 results: Hope to gather even more momentum later this year...
US Futures Tumble After Facebook Implodes; GDP Data On Deck
The three-day rebound from last week's rout ended with a thud after the close yesterday when Meta imploded, plunging as much...
Sanofi Sales, Profit Beat Expectations...
Key Events This Week: PCE, GDP, Fed Blackout And Earnings Gallore
Hot on the heels of last week's tech and momentum rout, shaken traders will have to wait until Friday for the main...
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts 150 cells/ L and 300...
Discover results from Sanofi's Phase 2 study on frexalimab for relapsing multiple sclerosis. Explore sustained reduction in disease activity and lesion numbers with low relapse rates.
read more...